158 related articles for article (PubMed ID: 25649442)
1. Benign (BI-RADS 2) lesions in breast MRI.
Spick C; Szolar DH; Tillich M; Reittner P; Preidler KW; Baltzer PA
Clin Radiol; 2015 Apr; 70(4):395-9. PubMed ID: 25649442
[TBL] [Abstract][Full Text] [Related]
2. Frequency of Malignancy and Imaging Characteristics of Probably Benign Lesions Seen at Breast MRI.
Grimm LJ; Anderson AL; Baker JA; Johnson KS; Walsh R; Yoon SC; Ghate SV
AJR Am J Roentgenol; 2015 Aug; 205(2):442-7. PubMed ID: 26204298
[TBL] [Abstract][Full Text] [Related]
3. Rate of malignancy in MRI-detected probably benign (BI-RADS 3) lesions.
Spick C; Szolar DH; Baltzer PA; Tillich M; Reittner P; Preidler KW; Pinker-Domenig K; Helbich TH
AJR Am J Roentgenol; 2014 Mar; 202(3):684-9. PubMed ID: 24555608
[TBL] [Abstract][Full Text] [Related]
4. Probably benign breast MRI lesions: frequency, lesion type, and rate of malignancy.
Lourenco AP; Chung MT; Mainiero MB
J Magn Reson Imaging; 2014 Apr; 39(4):789-94. PubMed ID: 24108546
[TBL] [Abstract][Full Text] [Related]
5. False-positive findings at contrast-enhanced breast MRI: a BI-RADS descriptor study.
Baltzer PA; Benndorf M; Dietzel M; Gajda M; Runnebaum IB; Kaiser WA
AJR Am J Roentgenol; 2010 Jun; 194(6):1658-63. PubMed ID: 20489110
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of probably benign breast MRI lesions.
Eby PR; DeMartini WB; Gutierrez RL; Saini MH; Peacock S; Lehman CD
AJR Am J Roentgenol; 2009 Sep; 193(3):861-7. PubMed ID: 19696303
[TBL] [Abstract][Full Text] [Related]
7. [Stereotactic Mammotome breast biopsy: routine clinical experience and correlation with BI-RADS--classification and histopathology].
Michel SC; Löw R; Singer G; Otto R; Hohl M; Kubik RA
Praxis (Bern 1994); 2007 Sep; 96(39):1459-74. PubMed ID: 17966279
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging of the breast as a problem-solving method: to be or not to be?
Oztekin PS; Kosar PN
Breast J; 2014; 20(6):622-31. PubMed ID: 25200378
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostic value of a breast MRI score for the prediction of malignancy of breast lesions detected solely with MRI].
Siegmann KC; Moron HU; Baur A; Hahn M; Vogel U; Claussen CD; Bitzer M
Rofo; 2009 Jun; 181(6):556-63. PubMed ID: 19452398
[TBL] [Abstract][Full Text] [Related]
10. BI-RADS® 3 lesions at contrast-enhanced breast MRI: is an initial short-interval follow-up necessary?
Bahrs SD; Baur A; Hattermann V; Hahn M; Vogel U; Claussen CD; Siegmann-Luz KC
Acta Radiol; 2014 Apr; 55(3):260-5. PubMed ID: 23969262
[TBL] [Abstract][Full Text] [Related]
11. Frequency of malignancy in lesions classified as probably benign after dynamic contrast-enhanced breast MRI examination.
Sadowski EA; Kelcz F
J Magn Reson Imaging; 2005 May; 21(5):556-64. PubMed ID: 15834907
[TBL] [Abstract][Full Text] [Related]
12. Screening breast MR imaging: comparison of interpretation of baseline and annual follow-up studies.
Abramovici G; Mainiero MB
Radiology; 2011 Apr; 259(1):85-91. PubMed ID: 21285337
[TBL] [Abstract][Full Text] [Related]
13. BI-RADS lesion characteristics predict likelihood of malignancy in breast MRI for masses but not for nonmasslike enhancement.
Gutierrez RL; DeMartini WB; Eby PR; Kurland BF; Peacock S; Lehman CD
AJR Am J Roentgenol; 2009 Oct; 193(4):994-1000. PubMed ID: 19770321
[TBL] [Abstract][Full Text] [Related]
14. Improved differentiation of benign and malignant breast tumors with multiparametric 18fluorodeoxyglucose positron emission tomography magnetic resonance imaging: a feasibility study.
Pinker K; Bogner W; Baltzer P; Karanikas G; Magometschnigg H; Brader P; Gruber S; Bickel H; Dubsky P; Bago-Horvath Z; Bartsch R; Weber M; Trattnig S; Helbich TH
Clin Cancer Res; 2014 Jul; 20(13):3540-9. PubMed ID: 24963052
[TBL] [Abstract][Full Text] [Related]
15. Role of breast MR imaging for predicting malignancy of histologically borderline lesions diagnosed at core needle biopsy: prospective evaluation.
Pediconi F; Padula S; Dominelli V; Luciani M; Telesca M; Casali V; Kirchin MA; Passariello R; Catalano C
Radiology; 2010 Dec; 257(3):653-61. PubMed ID: 20884914
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and Outcomes of BI-RADS 3 Lesions on Breast MRI.
Panigrahi B; Harvey SC; Mullen LA; Falomo E; Di Carlo P; Lee B; Myers KS
Clin Breast Cancer; 2019 Feb; 19(1):e152-e159. PubMed ID: 30268764
[TBL] [Abstract][Full Text] [Related]
17. Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution.
Kuhl CK; Schild HH; Morakkabati N
Radiology; 2005 Sep; 236(3):789-800. PubMed ID: 16118161
[TBL] [Abstract][Full Text] [Related]
18. Characteristics, Malignancy Rate, and Follow-up of BI-RADS Category 3 Lesions Identified at Breast MR Imaging: Implications for MR Image Interpretation and Management.
Chikarmane SA; Birdwell RL; Poole PS; Sippo DA; Giess CS
Radiology; 2016 Sep; 280(3):707-15. PubMed ID: 27089027
[TBL] [Abstract][Full Text] [Related]
19. Interobserver Variability Between Breast Imagers Using the Fifth Edition of the BI-RADS MRI Lexicon.
Grimm LJ; Anderson AL; Baker JA; Johnson KS; Walsh R; Yoon SC; Ghate SV
AJR Am J Roentgenol; 2015 May; 204(5):1120-4. PubMed ID: 25905951
[TBL] [Abstract][Full Text] [Related]
20. MR imaging in probably benign lesions (BI-RADS category 3) of the breast.
Gökalp G; Topal U
Eur J Radiol; 2006 Mar; 57(3):436-44. PubMed ID: 16316732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
